Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Mitchell, E. P.
Lacouture, M.
Shearer, H.
Iannotti, N.
Piperdi, B.
Pillai, M.
Xu, F.
Yassine, M.
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] Piedmont Hematol Oncol Associates PLLC, Winston Salem, NC USA
[4] Hematol Oncol Associates Treasure Coast, Port St Lucie, FL USA
[5] Univ Massachusetts, Med Ctr, Worcester, MA USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4027
引用
收藏
页数：1
相关论文
共 50 条
  • [21] RANDOMIZED PHASE 3 STUDY OF PANITUMUMAB (PMAB) WITH FOLFIRI COMPARED TO FOLFIRI ALONE AS SECOND-LINE TREATMENT (TX) FOR METASTATIC COLORECTAL CANCER (MCRC): SECONDARY ENDPOINT RESULTS
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
  • [22] Pooled safety results from SPIRITT: A multicenter, open-label, randomized, phase II study of FOLFIRI with panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Hecht, J. R.
    Dakhil, S. R.
    Saleh, M. N.
    Piperdi, B.
    Cline-Burkhardt, M.
    Kocs, D. M.
    DeMarco, L. C.
    Chen, L.
    Krishnan, K.
    Cohn, A. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [23] Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC)
    Douillard, J.
    Siena, S.
    Cassidy, J.
    Tabernero, J.
    Burkes, R. L.
    Barugel, M. E.
    Humblet, Y.
    Cunningham, D.
    Xu, F.
    Krishnan, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
    Eng, Cathy
    Van Cutsem, Eric
    Nowara, Elzbieta
    Swieboda-Sadlej, Anna
    Tebbutt, Niall C.
    Mitchell, Edith P.
    Davidenko, Irina
    Lee, Oliver
    Oliner, Kelly Smith
    Schupp, Marco
    Loh, Elwyn
    Sidhu, Roger
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [25] PEAK (STUDY 20070509): A RANDOMISED PHASE 2 STUDY OF mFOLFOX6 WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 1ST-LINE TREATMENT (tx) IN PATIENTS (pts) WITH UNRESECTABLE WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)
    Schwartzberg, L.
    Rivera, F.
    Karthaus, M.
    Fasola, G.
    Canon, J. -L.
    Yu, H.
    Go, W.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 62 - 62
  • [26] Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC)
    Peeters, Marc
    Oliner, Kelly S.
    Price, Timothy Jay
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew
    Wilson, Gregory
    Ciuleanu, Tudor-Eliade
    Roman, Laslo
    Van Cutsem, Eric
    Tian, Ying
    Jung, Andre Scott
    Sidhu, Roger
    Patterson, Scott D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [27] PANITUMUMAB (PMAB) IN COMBINATION WITH CHEMOTHERAPY (CT) VERSUS CT ALONE: HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC)
    Peeters, Marc
    Bennett, Lee
    Zhao, Zhongyun
    Barber, Beth
    Zhou, Xiaolei
    Zhang, Jessica
    Xu, Feng
    Wiezorek, Jeffery
    Douillard, Jean-Yves
    ANNALS OF ONCOLOGY, 2011, 22 : v24 - v24
  • [28] Final results from PRECEPT: efficacy and safety of second-line treatment with panitumumab and FOLFIRI in patients with metastatic colorectal cancer (mCRC)
    Cohn, A.
    Smith, D. A.
    Neubauer, M. A.
    Richards, D.
    Watkins, D. L.
    Zhang, K.
    Yassine, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 347 - 347
  • [29] Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    EJC SUPPLEMENTS, 2009, 7 (03): : 10 - 10
  • [30] Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).
    Peeters, Marc
    Douillard, Jean-Yves
    Van Cutsem, Eric
    Siena, Salvatore
    Zhang, Kathy
    Williams, Richard Thomas
    Wiezorek, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345